| Literature DB >> 34016285 |
Julie M Steinbrink1, Marisa H Miceli2.
Abstract
Mucormycosis is a rare but aggressive fungal disease that mainly affects patients with poorly controlled diabetes mellitus and those who are severely immunocompromised, including patients with hematological malignancies and solid organ transplant recipients. Early recognition of infection is critical for treatment success, followed by prompt initiation of antifungal therapy with lipid formulation amphotericin B. Posaconazole and isavuconazole should be used for stepdown and salvage therapy. Surgical debridement is key for tissue diagnosis and treatment and should be pursued urgently whenever possible. In addition to surgery and antifungal therapy, reverting the underlying risk factor for infection is important for treatment response.Entities:
Keywords: Diabetes mellitus; Immunocompromised host; Mucorales; Mucormycosis
Mesh:
Substances:
Year: 2021 PMID: 34016285 DOI: 10.1016/j.idc.2021.03.009
Source DB: PubMed Journal: Infect Dis Clin North Am ISSN: 0891-5520 Impact factor: 5.982